Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Summary
Sanofi has received conditional marketing authorization from the European Commission for Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and children aged 12 and older. This approval follows a positive opinion from the European Medicines Agency's CHMP on January 30, 2026, and an earlier 'EU Rezurock Nod' mentioned in a February 6, 2026 6-K filing, indicating the market had some anticipation of this outcome. The authorization expands Rezurock's market access to the EU, adding to its existing approvals in the US, UK, Canada, and China, and addresses a significant unmet medical need for patients with limited treatment options. The conditional nature requires completion of a confirmatory study, which will be a key factor to watch for full authorization.
At the time of this announcement, SNY was trading at $46.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.6B. The 52-week trading range was $43.32 to $56.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.